2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3940 IRF4 super-enhancer remodeling is associated with dexamethasone response and BATF-mediated resistance in multiple myeloma

Yusuke Yamashita, MD, PhD, Yuan Xiao Zhu, PhD2, Yuliza Tafoya Alvarado, MS3, Yixuan Zhu4, Chang-Xin Shi, PhD5, Caleb Karl Stein, PhD6, Megan T. Du, MS7, Meaghen Sharik, BS8, Kirsten Pfeffer, PhD9, Erin Meermeier, PhD10, Benjamin Gabriel Barwick, PhD11, Marta Chesi, PhD12, P. Leif Bergsagel, MD13
1 Mayo Clinic Arizona, Scottsdale, Arizona, United States, Wakayama Medical University, Wakayama, Japan
2 Mayo Clinic Arizona, Scottsdale, Arizona, United States
3 Mayo Clinic Arizona, Scottsdale, Arizona, United States
4 Mayo Clinic Arizona, Scottsdale, Arizona, United States, The University of Tokyo, Tokyo, Japan
5 Mayo Clinic Arizona, Scottsdale, Arizona, United States
6 Mayo Clinic Arizona, Scottsdale, Arizona, United States
7 Mayo Clinic Arizona, Scottsdale, Arizona, United States
8 Mayo Clinic Arizona, Scottsdale, Arizona, United States
9 Mayo Clinic Arizona, Scottsdale, Arizona, United States
10 Mayo Clinic, Scottsdale, Arizona, United States
11 Emory University School of Medicine, Atlanta, Georgia, United States
12 Mayo Clinic Arizona, Scottsdale, Arizona, United States
13 Mayo Clinic Arizona, Scottsdale, Arizona, United States

Introduction: Dexamethasone (DEX) is a cornerstone of MM therapy, however, its molecular mechanisms of action remain incompletely understood. MM cell survival depends on lineage-defining transcription factors such as IRF4, whose expression is regulated by plasma cell super-enhancers (SEs). Because epigenetic remodeling of SEs has been implicated in therapeutic response to some anti-MM agents, we investigated whether DEX alters H3K27ac at myeloma SE. We further examined whether BATF, an AP-1 transcription factor that hetero-dimerizes with IRF4 to regulate SE-associated transcriptional programs and has been implicated in resistance to immunomodulatory drugs (IMiDs), contributes to DEX resistance.

Methods: Four human myeloma cell lines (HMCLs) were used to assess sensitivity to DEX. IRF4 mRNA expression levels were quantified by qPCR. H3K27ac occupancy at the DUSP22/IRF4 locus was assessed by chromatin immunoprecipitation (ChIP)-qPCR, and representative samples were analyzed by ChIP-seq. HMCLs overexpressing (O/E) BATF, BATFH55Q (an IRF4 interaction-deficient mutant), or GFP were generated by lentiviral transduction and subjected to DEX sensitivity, competitive growth, and gene expression analyses. To evaluate the clinical significance of BATF expression, publicly available datasets from the CoMMpass IA22 cohort of newly diagnosed MM (NDMM) patients (n=737), paired diagnosis/progression samples (n=65), and an independent validation cohort (GSE24080, n=559) were analyzed.

Results: Among the four tested HMCLs, MM.1S and KMS34 were highly sensitive to DEX (IC50: <2.5nM) and exhibited 60-70% reductions in IRF4 mRNA levels after 6 hours of treatment. In contrast, OPM2 showed intermediate sensitivity (IC50: 16nM) with only modest IRF4 mRNA downregulation (approximately 20%), whereas IRF4 expression was largely maintained in the resistant cell line KMS11 (IC50: >1μM). In DEX-sensitive HMCLs, 6-hour DEX treatment (500 nM for KMS34 and 1 μM for MM.1S and OPM2) reduced H3K27ac occupancy at the DUSP22/IRF4 locus by approximately 50%, and ChIP-seq analysis in KMS34 demonstrated reduced H3K27ac at multiple super-enhancers regulating key myeloma genes, including DUSP22/IRF4, MYC, XBP1, and POU2AF1. In OPM2 cells, BATF O/E conferred resistance to DEX (IC50: >1 μM) and attenuated IRF4 downregulation, while only partial resistance was observed by O/E of a BATFH55Q mutation that impairs IRF4 hetero-dimerization. Consistent with these findings, competitive growth assays in three HMCLs demonstrated preferential selection of BATF O/E cells and modest enrichment of BATFH55Q cells under DEX treatment, indicating a role for BATF and its heterodimerization with IRF4 in DEX resistance.

In the CoMMpass NDMM cohort, patients were stratified by median BATF expression. High BATF expression was significantly associated with inferior overall survival (OS, p<0.0001, HR=1.68) and progression-free survival (PFS, p=0.0002, HR=1.43). These associations remained significant in multivariable analyses adjusting for ISS stage, high-risk cytogenetic abnormalities and age (OS, p=0.018, HR=1.38; PFS, p=0.019, HR=1.28). BATF expression, analyzed as a continuous variable, also remained independently associated with inferior OS (p=0.013, HR=1.15) and PFS (p=0.009, HR=1.13). These findings were validated in an independent dataset (GSE24080, n=559), in which high BATF expression was likewise associated with shorter OS (p=0.007, HR=1.51) and event-free survival (EFS, p=0.027, HR=1.33). Furthermore, paired analysis of 65 patients from the CoMMpass cohort revealed that BATF expression was significantly increased at disease progression, after DEX exposure, compared to diagnosis (p=0.0015).

Conclusions: DEX decreases MM cell viability and suppresses IRF4 expression in DEX-sensitive HMCLs, accompanied by reduced H3K27ac at the DUSP22/IRF4 super-enhancer. BATF attenuates DEX-induced IRF4 suppression and confers DEX resistance, with preferential selection of BATF O/E cells under therapeutic pressure. Clinically, high BATF expression is associated with inferior survival and increased expression at disease progression. Together, these findings suggest that DEX-induced changes in H3K27ac at key myeloma super-enhancers represent a previously unrecognized mechanism associated with DEX response and implicate BATF as a mediator of DEX resistance in MM.

Yusuke Yamashita, MD, PhD: No relevant conflicts of interest to declare.